Search Results - Steven Knapper

Refine Results
  1. 1
    FLT3 inhibition in acute myeloid leukaemia

    FLT3 inhibition in acute myeloid leukaemia by Steven Knapper

    Published 2007
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine

    The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine by Elisabeth Walsby, Steven Coles, Steven Knapper, Alan K. Burnett

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

    The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cas... by Steven Knapper, Ken Mills, Amanda Gilkes, Steve J. Austin, V. Walsh, Alan K. Burnett

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series

    Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series by Yan Beauverd, D. Radia, Catherine Cargo, Steven Knapper, Mark W. Drummond, Anand Pillai, Claire Harrison, Susan Robinson

    Published 2016
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  5. 5
    The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse

    The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse by Steven Coles, Marie Gilmour, Reiss A. Reid, Steven Knapper, Alan K. Burnett, Stephen Man, Alex Tonks, Richard L. Darley

    Published 2015
    Get full text
    Carta
    Save to List
    Saved in:
  6. 6
    FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

    FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo by Takashi Sato, Xiaochuan Yang, Steven Knapper, P. Bruce White, B. Douglas Smith, Steven Galkin, Donald Small, Alan Burnett, Mark J. Levis

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

    A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy by Steven Knapper, Alan K. Burnett, Tim Littlewood, William J. Kell, Sam Agrawal, Raj Chopra, Richard E. Clark, Mark J. Levis, Donald Small

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

    Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival by Alan K. Burnett, Nigel H. Russell, Ann E. Hunter, Donald Milligan, Steven Knapper, Keith Wheatley, John Yin, Mary Frances McMullin, Sahra Ali, David Bowen, Robert K. Hills

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial

    Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial by Adam J. Mead, Dragana Milojković, Steven Knapper, Mamta Garg, Joseph Chacko, Mira Farquharson, John Liu Yin, Sahra Ali, Richard E. Clark, Chris Andrews, Meryem Ktiouet Dawson, Claire Harrison

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia

    Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia by Naeem Khan, Robert K. Hills, Paul Virgo, Stephen Couzens, Nithiya Clark, Amanda Gilkes, Peter Richardson, Steven Knapper, David Grimwade, Nigel H. Russell, Alan K. Burnett, Sylvie D. Freeman

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Evidence of Person-to-Person Transmission of Oseltamivir-Resistant Pandemic Influenza A(H1N1) 2009 Virus in a Hematology Unit

    Evidence of Person-to-Person Transmission of Oseltamivir-Resistant Pandemic Influenza A(H1N1) 2009 Virus in a Hematology Unit by Catherine Moore, Mónica Galiano, Angie Lackenby, Tamir Abdelrahman, Rosemary A. Barnes, M.R. Evans, Chris Fegan, Susannah Froude, Mark Hastings, Steven Knapper, Emma Litt, Nicola Price, R Salmon, Mark Temple, Eleri Davies

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

    A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML by Steven Knapper, Nigel H. Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Helmut König, Mark J. Levis, Alan K. Burnett

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Guideline for the investigation and management of eosinophilia

    Guideline for the investigation and management of eosinophilia by Nauman M. Butt, Jonathan Lambert, Sahra Ali, Philip Beer, Nicholas C.P. Cross, Andrew Duncombe, Joanne Ewing, Claire Harrison, Steven Knapper, Donal P. McLornan, Adam J. Mead, Deepti Radia, Barbara J. Bain

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis

    A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis by Mary Frances McMullin, Adam J. Mead, Sahra Ali, Catherine Cargo, Frederick Chen, Joanne Ewing, Mamta Garg, Anna L. Godfrey, Steven Knapper, Donal P. McLornan, Jyoti Nangalia, Mallika Sekhar, Frances Wadelin, Claire Harrison

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline

    A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline by Mary Frances McMullin, Claire Harrison, Sahra Ali, Catherine Cargo, Frederick Chen, Joanne Ewing, Mamta Garg, Anna L. Godfrey, Steven Knapper, Donal P. McLornan, Jyoti Nangalia, Mallika Sekhar, Frances Wadelin, Adam J. Mead

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia

    Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia by Bader S. Alanazi, Chinmay Munje, Namrata Rastogi, Andrew J.K. Williamson, Samuel Taylor, Paul S. Hole, Marie Hodges, Michelle J. Doyle, Sarah M. Baker, Amanda Gilkes, Steven Knapper, Andrew Pierce, Anthony D. Whetton, Richard L. Darley, Alex Tonks

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Guideline for the diagnosis and management of myelofibrosis

    Guideline for the diagnosis and management of myelofibrosis by John T. Reilly, Mary Frances McMullin, Philip Beer, Nauman M. Butt, Eibhlin Conneally, Andrew Duncombe, Anthony R. Green, N. George Michaeel, Maria Gilleece, Georgina Hall, Steven Knapper, Adam J. Mead, Ruben A. Mesa, Mallika Sekhar, Bridget S. Wilkins, Claire Harrison

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

    A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial by Jad Othman, Charlotte S. Wilhelm-Benartzi, Richard Dillon, Steven Knapper, Sylvie D. Freeman, Leona Batten, Joanna Canham, Emily Laura Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

    Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial by Sylvie D. Freeman, Abin Thomas, Ian Thomas, Robert K. Hills, Paresh Vyas, Amanda Gilkes, Marlen Metzner, Niels Asger Jakobsen, Alison Kennedy, Rachel Moore, Nuria Marquez Almuina, Sarah S. Burns, Sophie King, Georgia Andrew, Kathleen Gallagher, Rob S. Sellar, Paul Cahalin, Duruta Weber, Mike Dennis, Priyanka Mehta, Steven Knapper, Nigel H. Russell

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

    Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide by Claire Harrison, Adam J. Mead, Anesh Panchal, Sonia Fox, Christina Yap, Emmanouela Gbandi, Aimee E. Houlton, Samah Alimam, Joanne Ewing, Marion Wood, Frederick Chen, Jason Coppell, Nicki Panoskaltsis, Steven Knapper, Sahra Ali, Angela Hamblin, Robyn M. Scherber, Amylou C. Dueck, Nicholas C.P. Cross, Ruben A. Mesa, Mary Frances McMullin

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: